Parkinson's Disease

Neurology
122
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
11
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
37
7
24
0
32
22
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Gene Therapy
375%
Monoclonal Antibody
125%
+ 134 programs with unclassified modality

On Market (11)

Approved therapies currently available

Teva
AZILECTApproved
rasagiline mesylate
Teva
oral2006
E
DAYVIGOApproved
lemborexant
Eisai
Orexin Receptor Antagonist [EPC]oral2019
UP
KEPPRAApproved
levetiracetam
UCB Pharma
oral1999
UP
KEPPRA XRApproved
levetiracetam
UCB Pharma
oral2008
U
LEVETIRACETAMApproved
levetiracetam
Unknown Company
oral2009
UP
NEUPROApproved
rotigotine
UCB Pharma
Nonergot Dopamine Agonist [EPC]transdermal2007
Kyowa Hakko Kirin
NOURIANZApproved
istradefylline
Kyowa Hakko Kirin
oral2019
U
PERAMPANELApproved
perampanel
Unknown Company
Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]oral2025
U
RASAGILINE MESYLATEApproved
rasagiline mesylate
Unknown Company
oral2013
U
SAFINAMIDEApproved
safinamide
Unknown Company
oral
U
SPRITAMApproved
levetiracetam
Unknown Company
oral2015

Competitive Landscape

34 companies ranked by most advanced pipeline stage

UP
21 programs
6
2
9
3
LevetiracetamPhase 41 trial
ParcopaPhase 41 trial
RotigotinePhase 41 trial
PARCOPAPhase 31 trial
ParcopaPhase 31 trial
+16 more programs
Active Trials
NCT04179695Recruiting120Est. Dec 2026
NCT00292227Completed130Est. Oct 2006
NCT01964573Completed48Est. Feb 2007
+18 more trials
Teva
TevaIsrael - Petach Tikva
16 programs
1
7
4
RasagilinePhase 41 trial
RasagilinePhase 41 trial
RasagilinePhase 41 trial
rasagiline mesylatePhase 41 trial
Rasagiline MesylatePhase 31 trial
+11 more programs
Active Trials
NCT02384512Completed261Est. Jan 2015
NCT02207387Unknown60Est. Mar 2017
NCT00932581Completed110Est. Dec 2009
+14 more trials
E
13 programs
7
5
1
LemborexantPhase 41 trial
2 mg perampanelPhase 31 trial
E2007Phase 31 trial
E2007Phase 31 trial
PerampanelPhase 31 trial
+8 more programs
Active Trials
NCT00165789Completed75Est. Sep 2006
NCT00451633Withdrawn0
NCT01172379Completed2
+10 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
1
orally disintegrating selegilinePhase 41 trial
Fipamezole ODTN/A1 trial
Fipamezole ODTN/A1 trial
Active Trials
NCT01149811CompletedEst. Nov 2010
NCT01140841CompletedEst. Nov 2010
NCT00443872CompletedEst. Dec 2008
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
3 programs
1
2
1
NOURIANZ(Istradefylline)Phase 35 trials
IstradefyllinePhase 31 trial
Istradefylline 40 mgPhase 11 trial
Active Trials
NCT02174250Completed20Est. Dec 2014
NCT05885360Completed27Est. Feb 2025
NCT05182151Terminated8Est. Dec 2023
+4 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
1
1
1
Levodopa/carbidopa/entacaponePhase 41 trial
EntacaponePhase 21 trial
TCH346Phase 1/21 trial
Active Trials
NCT00407212Completed301Est. Nov 2003
NCT00237263Completed285Est. Jul 2007
NCT00391898Completed95Est. Jun 2008
Ipsen
IpsenChina - Tianjin
1 program
1
Tigan®Phase 41 trial
Active Trials
NCT00489255Completed117Est. Mar 2012
Bial
14 programs
10
2
2
BIA 9-1067Phase 31 trial
BIA 9-1067Phase 31 trial
BIA 28-6156 10 mgPhase 21 trial
BIA 9-1067Phase 21 trial
BIA 3-202Phase 11 trial
+9 more programs
Active Trials
NCT02763852CompletedEst. Jul 2001
NCT02763839CompletedEst. Jul 2001
NCT02774564CompletedEst. Nov 2005
+11 more trials
Newron Pharmaceuticals
7 programs
1
2
4
SafinamidePhase 31 trial
SafinamidePhase 31 trial
SafinamidePhase 31 trial
SafinamidePhase 31 trial
i.c.v. infusion of sNN0031 by an Implanted infusion systemPhase 1/21 trial
+2 more programs
Active Trials
NCT01829867TerminatedEst. Oct 2015
NCT02408562TerminatedEst. Oct 2015
NCT00866502CompletedEst. Mar 2011
+4 more trials
Prothena
ProthenaDUBLIN 2, Ireland
4 programs
2
1
1
PrasinezumabPhase 3Monoclonal Antibody1 trial
RO7046015Phase 21 trial
PRX002Phase 11 trial
PRX002Phase 11 trial
Active Trials
NCT02157714Completed64
NCT02095171Completed40
NCT03100149Active Not Recruiting316Est. Dec 2031
+1 more trials
Takeda
TakedaTOKYO, Japan
3 programs
2
TVP-1012Phase 31 trial
TVP-1012 1mgPhase 32 trials
RasagilineN/A1 trial
Active Trials
NCT03727139Completed1,021Est. Oct 2021
NCT02337725Completed244Est. Sep 2016
NCT02337751Completed198Est. Mar 2017
+1 more trials
Biogen
BiogenCAMBRIDGE, MA
6 programs
3
3
BIIB014Phase 21 trial
BIIB014Phase 21 trial
active drugPhase 21 trial
BIIB054Phase 11 trial
BIIB054Phase 11 trial
+1 more programs
Active Trials
NCT02459886Completed66Est. Nov 2017
NCT03716570Terminated24Est. Apr 2021
NCT04056689Completed36Est. Dec 2020
+3 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
1
2
NR2B NMDA Antagonist CP-101,606Phase 21 trial
Premarin ®Phase 21 trial
PF-06649751Phase 11 trial
Active Trials
NCT02224664Completed50Est. Mar 2016
NCT00163085Completed12Est. Jan 2006
NCT00234676Completed23Est. Mar 2006
Sanofi
SanofiPARIS, France
2 programs
1
1
Fetal porcine cells, Neurocell-PDPhase 21 trial
AAV-hAADC-2Phase 1Gene Therapy1 trial
Active Trials
NCT00229736Completed10Est. Mar 2013
NCT00226460CompletedEst. Jan 2001
Cerevance
CerevanceMA - Boston
2 programs
1
1
CVN424 150 mgPhase 21 trial
CVN424Phase 11 trial
Active Trials
NCT05635461CompletedEst. Nov 2022
NCT06006247CompletedEst. Feb 2025
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
CX-8998Phase 21 trial
Active Trials
NCT03436953Withdrawn0Est. Dec 2020
Clene
CleneSALT LAKE CITY, UT
1 program
1
Gold NanocrystalsPhase 21 trial
Active Trials
NCT03815916CompletedEst. Jun 2021
Acadia Pharmaceuticals
1 program
1
PimavanserinPhase 21 trial
Active Trials
NCT04164758Terminated11Est. Sep 2020
DS
Daiichi SankyoChina - Shanghai
1 program
1
piclozotanPhase 21 trial
Active Trials
NCT00623363Completed27Est. Jul 2008
MeiraGTx
MeiraGTxNEW YORK, NY
2 programs
2
AAV-GADPhase 1/2Gene Therapy1 trial
AAV-GAD Low DosePhase 1/2Gene Therapy1 trial
Active Trials
NCT05894343Active Not RecruitingEst. Oct 2029
NCT05603312CompletedEst. Sep 2024
Oxford Biomedica
Oxford BiomedicaMA - Bedford
2 programs
2
ProSavinPhase 1/21 trial
ProSavinPhase 1/21 trial
Active Trials
NCT00627588Completed15Est. Aug 2012
NCT01856439Terminated15Est. Apr 2022
AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
1
ABBV-0805Phase 11 trial
Duodopa Home Titration Using Telemedicine: Evaluation of Use of ResourcesN/A1 trial
Global REsponsE During iNFusIon of a gEl With LevoDopa/CarbidopaN/A
Psycho-social CBT based trainingN/A1 trial
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at N/A1 trial
Active Trials
NCT01956032Completed15Est. Nov 2014
NCT02048605Completed30Est. Jan 2017
NCT06916507Recruiting125Est. Sep 2027
+1 more trials
AskBio
AskBioNC - Durham
2 programs
1
AAV2-GDNFPhase 11 trial
ObservationN/A1 trial
Active Trials
NCT07081841Enrolling By Invitation132Est. Mar 2038
NCT04167540Active Not Recruiting11Est. Jun 2027
Voyager Therapeutics
2 programs
2
VY-AADC01Phase 11 trial
VY-AADC02Phase 11 trial
Active Trials
NCT01973543CompletedEst. Jan 2020
NCT03562494CompletedEst. Oct 2024
Ionis Pharmaceuticals
1 program
1
BIIB094Phase 11 trial
Active Trials
NCT03976349Completed62Est. Aug 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY3154207Phase 11 trial
Active Trials
NCT02562768Completed80Est. Mar 2017
M&
Merck & Co.RAHWAY, NJ
1 program
1
SCH 900800Phase 11 trial
Active Trials
NCT01500707Withdrawn0Est. Jul 2013
Serina Therapeutics
1
SER-214Phase 11 trial
Active Trials
NCT02579473UnknownEst. Dec 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
pramipexolePhase 11 trial
Active Trials
NCT00666653Completed13Est. May 2007
Alliance Pharmaceuticals
1 program
1
sargramostimPhase 13 trials
Active Trials
NCT01882010Completed37Est. Jan 2016
NCT00017121Completed40Est. Nov 2012
NCT00006483Completed27Est. Jan 2013

+4 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
EisaiLemborexant
Kyowa Hakko KirinIstradefylline
TevaRasagiline
TevaRasagiline
TevaRasagiline
UCB PharmaRotigotine
IpsenTigan®
Bausch Healthorally disintegrating selegiline
NovartisLevodopa/carbidopa/entacapone
UCB PharmaParcopa
Tevarasagiline mesylate
UCB PharmaLevetiracetam
ProthenaPrasinezumab
TakedaTVP-1012 1mg
TakedaTVP-1012

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 12,790 patients across 50 trials

NCT07384429EisaiLemborexant

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Start: Feb 2026Est. completion: Dec 202644 patients
Phase 4Not Yet Recruiting

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Start: Jan 2023Est. completion: Feb 202527 patients
Phase 4Completed
NCT01723228TevaRasagiline

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Start: Nov 2012Est. completion: Jan 2015170 patients
Phase 4Completed
NCT01049984TevaRasagiline

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Start: Dec 2009Est. completion: Oct 2012328 patients
Phase 4Completed
NCT01007630TevaRasagiline

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

Start: Nov 2009Est. completion: Jan 201436 patients
Phase 4Unknown

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery

Start: Sep 2007Est. completion: May 200814 patients
Phase 4Completed

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

Start: May 2007Est. completion: Mar 2012117 patients
Phase 4Completed
NCT00443872Bausch Healthorally disintegrating selegiline

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

Start: Mar 2007Est. completion: Dec 2008
Phase 4Completed
NCT00391898NovartisLevodopa/carbidopa/entacapone

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

Start: Oct 2006Est. completion: Jun 200895 patients
Phase 4Completed

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

Start: Oct 2006Est. completion: Nov 200820 patients
Phase 4Completed
NCT00399477Tevarasagiline mesylate

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

Start: Oct 2006Est. completion: Jul 2007200 patients
Phase 4Completed

Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease

Start: Mar 2006Est. completion: Jul 200934 patients
Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Start: Nov 2025Est. completion: Jun 2031900 patients
Phase 3Recruiting
NCT02337751TakedaTVP-1012 1mg

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

Start: Jul 2015Est. completion: Mar 2017198 patients
Phase 3Completed

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

Start: Feb 2015Est. completion: Sep 2016244 patients
Phase 3Completed
NCT02337764TakedaTVP-1012 1mg

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Start: Feb 2015Est. completion: Sep 2016222 patients
Phase 3Completed
NCT01227655BialBIA 9-1067

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Start: Mar 2011Est. completion: Jul 2012
Phase 3Completed
NCT01568073BialBIA 9-1067

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Start: Mar 2011Est. completion: Nov 2013
Phase 3Completed

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Start: Apr 2009Est. completion: Jun 2012
Phase 3Terminated

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Start: Aug 2007Est. completion: Aug 2010
Phase 3Completed

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Start: Jul 2007Est. completion: May 200984 patients
Phase 3Terminated

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Start: Jul 2007Est. completion: Dec 2007124 patients
Phase 3Completed

Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

Start: Jul 2007Est. completion: Apr 2008328 patients
Phase 3Terminated

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Start: Jul 2007Est. completion: Jul 2011514 patients
Phase 3Completed

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Start: May 2007Est. completion: Mar 2009287 patients
Phase 3Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Start: Jan 2007Est. completion: Feb 2009
Phase 3Completed

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Start: Oct 2006Est. completion: Apr 2008997 patients
Phase 3Terminated
NCT00368108Eisai2 mg perampanel

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Start: Aug 2006Est. completion: Jan 2008752 patients
Phase 3Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Start: Feb 2006Est. completion: Aug 2007702 patients
Phase 3Completed
NCT00256204TevaRasagiline Mesylate

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

Start: Nov 2005Est. completion: Jun 20091,174 patients
Phase 3Completed

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Start: Oct 2005Est. completion: Oct 2008504 patients
Phase 3Terminated

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Start: Jun 2005Est. completion: Jul 2007
Phase 3Completed

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Start: Jun 2005Est. completion: Aug 2005
Phase 3Completed

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Start: Dec 2004Est. completion: Jul 2005
Phase 3Completed

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Start: Nov 2004Est. completion: Oct 2005
Phase 3Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Start: Nov 2004Est. completion: Nov 2005405 patients
Phase 3Completed

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Start: Oct 2004Est. completion: May 20071,100 patients
Phase 3Completed

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Start: Jul 2004Est. completion: Dec 2005580 patients
Phase 3Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Start: Jun 2004Est. completion: Jan 2006230 patients
Phase 3Completed
NCT00203138Tevarasagiline mesylate

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Start: Jun 2004Est. completion: Dec 2006306 patients
Phase 3Completed

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Start: Jan 2004Est. completion: May 2004
Phase 3Completed
NCT01327859EisaiPrior Donepezil 5mg

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

Start: Mar 2003Est. completion: Jul 2006357 patients
Phase 3Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

Start: Aug 2002Est. completion: Dec 2008258 patients
Phase 3Completed
NCT00203164Tevarasagiline mesylate

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

Start: May 2002Est. completion: Sep 2006254 patients
Phase 3Completed
NCT00203177Tevarasagiline mesylate

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

Start: Oct 2001254 patients
Phase 3Completed
NCT00203125Tevarasagiline mesylate

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Start: Oct 2000Est. completion: Jan 200355 patients
Phase 3Completed
NCT00203034Tevarasagiline mesylate

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

Start: May 2000Est. completion: Jan 2003472 patients
Phase 3Completed
NCT00203060TevaRasagiline Mesylate

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

Start: Jul 1997Est. completion: Jul 2000404 patients
Phase 3Completed

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Start: Aug 2002Est. completion: Oct 2003
Phase 2/3Completed

BIIB014 Phase 2a Monotherapy

0
Phase 2Withdrawn

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

32 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 12,790 patients
30 companies competing in this space